» Articles » PMID: 26000160

Assessment of Patients with Idiopathic Inflammatory Myopathies and Isolated Creatin-kinase Elevation

Overview
Publisher Biomed Central
Date 2015 May 23
PMID 26000160
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by inflammation of the skeletal muscle. Weakness, mainly affecting the proximal muscles, is the cardinal muscular symptom in IIM. In patients with dermatomyositis, peculiar skin lesions are observed. The assessment of patients with IIM includes clinical and laboratory evaluation, and clinimetric measurements. Different tools have been proposed to measure muscular and extramuscular disease activity and damage in patients with IIM. A core set of measurements to use in clinical practice was recently proposed. Among laboratory features the increase of serum creatine kinase (CK) is considered a hallmark of muscle inflammation/damage. However, subjects with persistent CK elevation, without any evidence of a definite myopathy, are often seen in clinical practice and need a careful assessment. Indeed, CK blood levels can also increase in non-myopathic conditions, e.g. in case of intense physical exercise, assumption of some drugs (statins), muscular dystrophy, muscular trauma or in case of neuro-muscular disorders which all should be considered in the diagnostic work-up. The assessment of patients with IIM and hyperCKemia will be discussed in this paper.

Citing Articles

Diagnostic Value of Whole-Body MRI in Pediatric Patients with Suspected Rheumatic Diseases.

Ozga J, Ostrogorska M, Wojciechowski W, Zuber Z Medicina (Kaunas). 2024; 60(9).

PMID: 39336447 PMC: 11434450. DOI: 10.3390/medicina60091407.


Bone turnover markers and muscle decay indicator in patients with proximal femur fracture - a case-control study.

Lapinski M, Zarnovsky K, Czarzasta K, Maciag B, Maciag G, Adamska O Reumatologia. 2024; 62(2):121-127.

PMID: 38799774 PMC: 11114133. DOI: 10.5114/reum/187096.


Impaired muscle strength is associated with ultrastructure damage in myositis.

Aguilar-Vazquez A, Chavarria-Avila E, Salazar-Paramo M, Armendariz-Borunda J, Toriz-Gonzalez G, Rodriguez-Baeza M Sci Rep. 2022; 12(1):17671.

PMID: 36271295 PMC: 9586957. DOI: 10.1038/s41598-022-22754-4.


Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis.

Ross L, Lindqvist A, Costello B, Hansen D, Brown Z, Day J Arthritis Res Ther. 2022; 24(1):84.

PMID: 35410246 PMC: 8996589. DOI: 10.1186/s13075-022-02768-z.


Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.

Danieli M, Verga J, Mezzanotte C, Terrenato I, Svegliati S, Bilo M Front Immunol. 2022; 12:805705.

PMID: 35111165 PMC: 8801806. DOI: 10.3389/fimmu.2021.805705.


References
1.
Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

2.
Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J . Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2013; 31(3):428-32. View

3.
Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M . Overlap connective tissue disease syndromes. Autoimmun Rev. 2012; 12(3):363-73. DOI: 10.1016/j.autrev.2012.06.004. View

4.
Dalakas M, Hohlfeld R . Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. DOI: 10.1016/S0140-6736(03)14368-1. View

5.
Miller F, Rider L, Chung Y, Cooper R, Danko K, Farewell V . Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001; 40(11):1262-73. DOI: 10.1093/rheumatology/40.11.1262. View